Ketogenic diet review hints at brain-energy overlap with creatine

Key Takeaways

• This paper is a narrative review on ketogenic diets, not a clinical trial of creatine.
• The authors highlight overlapping mechanisms with creatine science: ATP buffering, mitochondrial function, and oxidative stress.
• The source suggests therapeutic potential in schizophrenia, bipolar disorder, and Alzheimer’s disease, but it does not prove efficacy.
• For creatine users, the practical takeaway is contextual: brain-energy support remains a credible research theme, but evidence is much stronger for monohydrate in exercise than for psychiatric use.
• If someone is considering creatine, standard evidence-based dosing still applies: 3-5 g/day maintenance, with optional loading.
• People with neurological or psychiatric conditions should treat both ketogenic diets and creatine as medical decisions, not DIY replacements for care.

What the review actually says

The new paper in International Journal of Molecular Sciences reviews how a ketogenic diet might affect biochemical pathways involved in schizophrenia, bipolar disorder, and Alzheimer’s disease. Its central claim is straightforward: by shifting energy production away from glucose and toward fats and ketone bodies, a ketogenic diet may alter brain bioenergetics in ways that could reduce oxidative stress, support mitochondrial function, and influence neurotransmitter balance.

That is the news here, but it is important to define the scope precisely. This is not a trial showing that ketogenic diets treat those conditions, and it is not a creatine study. It is a mechanistic and therapeutic overview arguing that several brain disorders share metabolic vulnerabilities, and that ketosis could potentially modulate some of them.

Why should creatine readers care? Because the paper focuses on an idea that also shows up repeatedly in creatine science: the brain is energetically expensive tissue, and disruptions in ATP handling, mitochondrial function, and oxidative stress may contribute to poor function or disease. Creatine’s role is different from ketosis, but both are discussed within the broader frame of cellular energy support.

For readers new to supplementation, our creatine guides explain why creatine monohydrate remains the benchmark form for evidence-based use, especially in sports nutrition. This review does not change that hierarchy. What it does do is reinforce why bioenergetics has become such an important lens in brain-health research.

Why creatine enters the conversation

Creatine was not tested in this review, yet the overlap in biological themes is real. Ketogenic diets increase reliance on fat oxidation and ketone bodies for fuel. Creatine, by contrast, helps buffer cellular energy through the phosphocreatine system, which can rapidly regenerate ATP during periods of high demand. Different tools, similar destination: more resilient energy handling.

That matters because the review highlights three recurring problems across the disorders it discusses:

• Mitochondrial dysfunction
• Oxidative stress
• Disturbed neurotransmitter balance

Those same themes often appear in discussions of creatine beyond the gym. The strongest evidence for creatine is still in exercise performance, lean mass support, and high-intensity training capacity, but researchers have long been interested in whether improving cellular energetics could also matter for cognition, recovery, or certain clinical populations.

The key caution is that mechanistic plausibility is not the same thing as proven benefit. A pathway can make biological sense without delivering large real-world effects in patients. That is true for ketogenic diets, and it is equally true for creatine in psychiatric or neurodegenerative settings.

If you are comparing options, start with practical fundamentals: creatine dosage calculator tools can help with basic intake planning, while our best creatine rankings and creatine brand reviews can help you evaluate monohydrate products. But this paper should be read as context for brain-energy science, not as evidence that creatine and ketosis are interchangeable.

Study design and limitations matter here

The biggest limitation is also the easiest to miss: this paper is a review article, based on the abstract provided, not a new randomized controlled trial. That means it synthesizes existing ideas and findings rather than generating fresh causal evidence. Reviews can be useful for spotting patterns and framing hypotheses, but they do not by themselves prove that an intervention works in patients.

In practice, several limitations follow from that:

• No direct creatine data: the source does not test creatine, compare creatine with ketogenic diets, or recommend a creatine protocol for these conditions.
• No single effect size: the abstract does not report one headline statistic showing how much symptoms improved.
• Broad disease grouping: schizophrenia, bipolar disorder, and Alzheimer’s disease are biologically and clinically distinct, even if they share some metabolic features.
• Mechanistic emphasis: claims about reducing oxidative stress or improving mitochondrial function are plausible, but clinical outcomes can lag behind mechanistic theory.

This is why responsible coverage has to separate what the review proposes from what is already proven. For creatine, the best-supported recommendations still come from broader evidence bases such as the ISSN position stand and the 2021 review on common creatine questions and misconceptions. Those sources support creatine monohydrate as safe and effective for many healthy users, especially in exercise contexts. They do not establish creatine as a treatment for psychiatric or neurodegenerative disease.

What this means in practice for people taking creatine

For most readers, the practical message is conservative: this paper does not change how you should use creatine for training, recovery, or general supplementation. If you are already taking creatine monohydrate, standard dosing remains the evidence-based default.

• Maintenance: 3-5 g/day
• Optional loading: about 20 g/day split into 4 doses for 5-7 days, then maintenance
• Timing: less important than consistency
• Form: monohydrate remains the most-studied option

If your interest is brain health rather than performance, this review adds conceptual support to the idea that energy metabolism matters. It does not tell you that adding creatine to a ketogenic diet will improve psychiatric symptoms, protect against Alzheimer’s disease, or outperform either approach alone. Those are unanswered questions.

There are also important safety and care-context issues. A ketogenic diet is a major dietary intervention, especially for people with complex medical conditions, medications, appetite issues, or metabolic comorbidities. Creatine is far simpler to use, but anyone with a neurological or psychiatric diagnosis should still involve a qualified clinician before treating supplements or diets as therapeutic tools.

If you are simply shopping for a reliable product, keep it boring and evidence-led. Browse the creatine product catalog for monohydrate options and use our broader creatine guides to avoid overpaying for forms with weaker evidence.

How this fits the bigger evidence base

This review fits into a larger trend in nutrition and neuroscience: interest in metabolic therapies for the brain. Ketogenic diets, fasting-related approaches, and bioenergetic supplements are all being studied because many neurological and psychiatric disorders appear to involve impaired energy handling at the cellular level.

For creatine specifically, the evidence base is uneven across use cases. In sports nutrition, it is unusually strong. The consensus view remains that creatine monohydrate can improve high-intensity exercise capacity and support training adaptations, with a strong safety profile in healthy populations when used appropriately. For a good mainstream evidence summary, see Antonio et al. (2021).

In brain and mental-health applications, the picture is more preliminary. There is scientific rationale, some promising lines of inquiry, and ongoing interest in ATP buffering, mitochondrial support, and neuroprotection. But readers should resist a common mistake: because ketosis and creatine both touch energy metabolism, it does not follow that they produce the same outcomes, in the same people, at the same magnitude.

The cleanest way to interpret this paper is as a reminder that metabolic dysfunction may be one shared thread across very different disorders. That strengthens the relevance of energy-focused research in general. It does not upgrade creatine from a well-supported sports supplement into a proven psychiatric or neurodegenerative therapy.

Bottom line

The paper’s main contribution is conceptual, not clinical. It argues that ketogenic diets may influence core biochemical problems seen in schizophrenia, bipolar disorder, and Alzheimer’s disease, especially mitochondrial dysfunction, oxidative stress, and altered neurotransmission. That is relevant to creatine readers because creatine research often centres on adjacent questions about ATP availability and cellular energy resilience.

But the guardrails matter. This source did not test creatine. It did not show that ketosis cures or clearly treats these disorders. And it did not provide a new dosing framework for people taking creatine for brain health.

So what should informed readers do with it? Treat it as evidence that brain-energy metabolism is an increasingly important research target. If you use creatine for training, this review does not change best practice: choose monohydrate, use a standard evidence-based dose, and be consistent. If you are interested in psychiatric or neurodegenerative applications, view both ketogenic diets and creatine as areas of active but incomplete research that require medical context.

That is less exciting than a miracle headline, but it is more useful. The overlap between ketosis and creatine is scientifically interesting. The proof for therapeutic outcomes, at least from this paper, is not there yet.

What this review means for creatine users

• 0 creatine trials in this paper — This source is a review of ketogenic diet mechanisms and therapeutic potential, not a creatine intervention study.
• 3 conditions highlighted — The abstract discusses schizophrenia, bipolar disorder, and Alzheimer’s disease.
• 3-5 g/day standard creatine maintenance dose — Mainstream creatine science supports this as a typical daily monohydrate dose.
• ~20 g/day optional loading dose — Usually split into 4 doses for 5-7 days before moving to maintenance.

Frequently Asked Questions

Sources & Further Reading

• Kreider et al. (2017), ISSN Position Stand: Safety and Efficacy of Creatine — JISSN
• Antonio et al. (2021), Common questions and misconceptions about creatine supplementation — JISSN